Abstract
Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease and to mitigate bone loss associated with cancer therapy in early stage disease. In addition, adjuvant breast cancer trials evaluating the oral bisphosphonate clodronate suggested a reduction in cancer recurrence, but the findings were mixed, with 2 positive and 1 negative report. In the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 study, adding the intravenous bisphosphonate zoledronic acid to endocrine therapy in premenopausal breast cancer patients significantly prolonged disease-free survival versus endocrine therapy alone (hazard ratio = 0.68; p = 0.008) at 62 months, and reduced local, regional, and distant recurrences. Clinical trial findings from other adjuvant trials (Z-FAST, ZO-FAST), neoadjuvant studies, and studies involving disseminated tumor cells (DTCs) are generally supportive of the ABCSG-12 conclusion, and recent data from AZURE suggest the importance of menopausal status. Preclinical studies provide data on the mechanisms of action that could mediate bisphosphonate direct and indirect anti-cancer effects. Recently, several observational studies (2 cohort studies and 2 case-control analyses) have associated oral bisphosphonate use with a lower breast cancer incidence. Such reports require cautious interpretation because confounding by indication is an issue: bisphosphonates are prescribed for women with low bone mineral density, and women with low bone density are at decreased breast cancer risk.
Keywords: Adjuvant treatment, Anti-cancer, Bisphosphonates, Early breast cancer, Prevention, Zoledronic acid, proliferation, clodronate, cancer risk
Anti-Cancer Agents in Medicinal Chemistry
Title: Bisphosphonates and Breast Cancer Prevention
Volume: 12 Issue: 2
Author(s): Rowan T. Chlebowski and Nananda Col
Affiliation:
Keywords: Adjuvant treatment, Anti-cancer, Bisphosphonates, Early breast cancer, Prevention, Zoledronic acid, proliferation, clodronate, cancer risk
Abstract: Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease and to mitigate bone loss associated with cancer therapy in early stage disease. In addition, adjuvant breast cancer trials evaluating the oral bisphosphonate clodronate suggested a reduction in cancer recurrence, but the findings were mixed, with 2 positive and 1 negative report. In the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 study, adding the intravenous bisphosphonate zoledronic acid to endocrine therapy in premenopausal breast cancer patients significantly prolonged disease-free survival versus endocrine therapy alone (hazard ratio = 0.68; p = 0.008) at 62 months, and reduced local, regional, and distant recurrences. Clinical trial findings from other adjuvant trials (Z-FAST, ZO-FAST), neoadjuvant studies, and studies involving disseminated tumor cells (DTCs) are generally supportive of the ABCSG-12 conclusion, and recent data from AZURE suggest the importance of menopausal status. Preclinical studies provide data on the mechanisms of action that could mediate bisphosphonate direct and indirect anti-cancer effects. Recently, several observational studies (2 cohort studies and 2 case-control analyses) have associated oral bisphosphonate use with a lower breast cancer incidence. Such reports require cautious interpretation because confounding by indication is an issue: bisphosphonates are prescribed for women with low bone mineral density, and women with low bone density are at decreased breast cancer risk.
Export Options
About this article
Cite this article as:
T. Chlebowski Rowan and Col Nananda, Bisphosphonates and Breast Cancer Prevention, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (2) . https://dx.doi.org/10.2174/187152012799014913
DOI https://dx.doi.org/10.2174/187152012799014913 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Significance of Various Experimental Models and Assay Techniques in Cancer Diagnosis
Mini-Reviews in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Isoflavones, Equol and Cardiovascular Disease: Pharmacological and Therapeutic Insights
Current Medicinal Chemistry The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Targeting Acetyl-CoA Carboxylase for Anti-obesity Therapy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Structural and Functional Organization of miRNAs
Current Pharmacogenomics Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Molecular Imaging of Tumor Angiogenesis and Therapeutic Effects with Dual Bioluminescence
Current Pharmaceutical Biotechnology LC/MS/MS Profiling of Tissue Oxysterols and its Application in Dextran Sodium Sulphate Induced Mouse Colitis Models
Current Topics in Medicinal Chemistry